Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Efalizumab].

V Descamps1

  • 1Université Paris VII Denis-Diderot, Service de Dermatologie, Hôpital Bichat Claude Bernard, APHP, 75018 Paris, France. vincent.descamps@bch.aphp.fr

Annales De Dermatologie Et De Venereologie
|October 21, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

French national protocol for diagnosis and management of drug reaction with eosinophilia and systemic symptoms (DRESS) in adults and children.

Annales de dermatologie et de venereologie·2025
Same author

French national protocol for diagnosis and management of epidermal necrolysis in adults (Stevens-Johnson syndrome and toxic epidermal necrolysis).

Annales de dermatologie et de venereologie·2024
Same author

Retrospective study on the association of human herpesvirus reactivation with severe DRESS: A description of blood and skin reactivations.

Journal of the European Academy of Dermatology and Venereology : JEADV·2023
Same author

[Enhancement of human herpesvirus 6 replication using sodium valproate].

Virologie (Montrouge, France)·2023
Same author

Erythema multiforme associated with anti-plakin antibodies: a multicentric retrospective case series.

Journal of the European Academy of Dermatology and Venereology : JEADV·2022
Same author

Efficacy of low-dose methotrexate in a short-regimen for granulomatous sarcoid-like reaction on permanent make-up during COVID-19 infection.

Journal of the European Academy of Dermatology and Venereology : JEADV·2022
Same journal

2024 guidelines (S3) for the therapeutic management of patients with genital herpes.

Annales de dermatologie et de venereologie·2026
Same journal

Topical JAK inhibitors in the lichen planus spectrum: a systematic review.

Annales de dermatologie et de venereologie·2026
Same journal

2024 recommendations for the therapeutic management of anogenital warts.

Annales de dermatologie et de venereologie·2026
Same journal

Successful use of thalidomide in treating metastatic Crohn's disease.

Annales de dermatologie et de venereologie·2026
Same journal

Multiple cutaneous juvenile xanthogranuloma: a monocentric study.

Annales de dermatologie et de venereologie·2026
Same journal

Cartilage-hair-hypoplasia associated with granulomatosis induced by rubella vaccine.

Annales de dermatologie et de venereologie·2026
See all related articles

Efalizumab is a biologic therapy for moderate-to-severe psoriasis, targeting T-lymphocyte adhesion molecules to reduce psoriatic plaque formation. While effective for skin lesions, it does not treat joint involvement and has potential side effects requiring monitoring.

Area of Science:

  • Immunology
  • Dermatology
  • Biotechnology

Background:

  • Psoriasis is a chronic inflammatory skin condition.
  • Biologic therapies offer novel treatment approaches for psoriasis.
  • Efalizumab targets the CD11a subunit of Leucocyte Function-associated Antigen-1 (LFA-1) on T lymphocytes.

Purpose of the Study:

  • To evaluate the efficacy and safety of efalizumab for moderate-to-severe plaque psoriasis.
  • To understand the mechanism of action of efalizumab in inhibiting T-lymphocyte interactions.

Main Methods:

  • Efalizumab is a humanised monoclonal antibody (IgG1).
  • It binds to CD11a on LFA-1, preventing interaction with Intercellular Adhesion Molecule-1 (ICAM-1).
  • Clinical trial data from 3500 patients with plaque psoriasis was analyzed.

Related Experiment Videos

Main Results:

  • Efalizumab demonstrated efficacy in reducing psoriatic plaque severity, with 22-39% of patients achieving a 75% improvement in PASI score compared to placebo.
  • Long-term data showed sustained efficacy in responders up to 36 months.
  • Common side effects include influenza-like syndrome; rare thrombocytopenia requires platelet count monitoring.

Conclusions:

  • Efalizumab is an approved treatment option for moderate-to-severe plaque psoriasis, particularly for patients who have failed other systemic therapies.
  • It is not effective for psoriatic joint involvement.
  • Its long-term benefit/risk ratio compared to other biotherapies, such as anti-TNF alpha agents, requires further evaluation.